stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Free cash flow
Mirum Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was $54.9M, compared with −$10.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$308.9M. Over the past ten years it has ranged from −$151.8M (fiscal 2021) to $54.9M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 4 consecutive fiscal years. Mirum Pharmaceuticals, Inc. ranks 568th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $54.9M | — |
| FY2024 | −$10.7M | — |
| FY2023 | −$91.1M | — |
| FY2022 | −$120.4M | — |
| FY2021 | −$151.8M | — |
| FY2020 | −$89.3M | — |
| FY2019 | −$39.6M | — |
| FY2018 | −$7.9M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$5.6M | — |
| Jun 2026 | −$69.3M | — |
| Mar 2026 | −$239.4M | — |
| Dec 2025 | $5.5M | (86.16%) |
| 29 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$101.2M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. compare | −$179.3M |
| PTCT PTC Therapeutics, Inc. compare | −$259.2M |
| MIRM Mirum Pharmaceuticals, Inc. | −$308.9M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$567.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement